NCT03720418View on ClinicalTrials.gov

Study of OXB-102 (AXO-Lenti-PD) in Patients With Bilateral, Idiopathic Parkinson's Disease

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

October 17, 2018

Primary Completion Date

April 12, 2022

Study Completion Date

April 12, 2022

Conditions
Parkinson Disease
Interventions
DRUG

OXB-102

Neurosurgical delivery of OXB-102 (gene therapy) to the putamen

OTHER

Imitation Surgical Procedure (ISP)

Participants randomized to the control group in Part B will receive an ISP

Trial Locations (3)

94010

Service de Neurochirurgie, Hôpital Henri Mondor, Créteil

CB2 0PY,

University of Cambridge, Centre for Brain Repair, Cambridge

WC1N 3BG

The National Hospital for Neurology and Neurosurgery, London

Sponsors

Lead Sponsor

Sio Gene Therapies
All Listed Sponsors
lead

Sio Gene Therapies

INDUSTRY